Investigation Report on China Repaglinide Market, 2010-2019

Publisher Name :
Date: 02-Jul-2015
No. of pages: 30

According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients has reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while that in America will reach 29.7 million. The fast growth of diabetes in China and other developing countries has put a heavy burden on their social and economic development.

There are about 90 million diabetes patients in today's China and 95% of them suffer from type 2 diabetes mellitus. And the number of potential patients might reach up to 200 million.??

Entering China after 2000, insulin secretagogues agent is mainly used for the treatment of type 2 diabetes. Currently, there are only 3 kinds available in the Chinese market, namely, nateglinide, repaglinide and mitiglinide. They share the same mechanism of action, that is to say, they lower blood glucose by stimulating the release of insulin from the beta cells. Compared with sulfonylurea, insulin secretagogues agent reports shorter duration of glucoselowering action and lower rate of hypoglycemia.

As an insulin secretagogues agent structured different from sulfonylurea, repaglinide is used to control postprandial hyperglycemia. Developed by Novo Nordisk A/S and BoehringerIngelheim together, it entered the United States in Apr. 1998.

As the first new prandial glucose regulator, repaglinide belongs to the class of benzoic acid derivative. Containing a chiral carbon atom, it has stereoselective activity and can be absorbed well on an empty stomach or not. As repaglinide is expelled from the body with bile after being metabolized by CYP3A4 enzyme system in the liver and only 6% of it is excreted through kidney, it is more suitable for patients with kidney disorders. Hence its advantage in the clinic. In 2000, repaglinide of Novo Nordisk A/S came to be sold in China under the name of Novonorm. According to CRI's market survey, it has few rivals and takes up a market share of about 89% for sales value while its main competitor Hanson Pharmaceutical only occupies less than 11% of the market. The sales value of repaglinide in sample hospitals was about CNY 125 million in 2014 and CAGR during the period of 20052014 reached about 22%.

The market size of repaglinide is expected to keep growing in the next few years in China.

Readers can get at least the following information through this report:


  • market size of repaglinide in China

  • major manufacturers of repaglinide for Chinese market and their market share

  • retail price of repaglinide in Chinese market

  • market outlook of repaglinide in China


The author suggests the following groups of people purchase this report:


  • manufacturers of antidiabetic drugs

  • investors/ research institutions interested in Chinese medicine market

  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Investigation Report on China Repaglinide Market, 2010-2019

Table of Contents

1 Related Concepts of Repaglinide
1.1 Indication
1.2 Sales Status in Global Market

2 Market Profile of Repaglinide in China
2.1 Patent Status
2.2 Major Manufacturers
2.3 Market Size

3 Survey on Sales Status of Repaglinide in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions

4 Survey on Market Share of Major Manufacturers of Repaglinide in China, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Survey on Dosage Forms of Repaglinide in China, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume

6 Reference Price of Repaglinide in Chinese Hospitals in 2014
6.1 Novo Nordisk A/S (Denmark)
6.2 Hanson Pharmaceutical
6.3 Tianjin Kangrui Pharmaceutical Co., Ltd
6.4 Beijing Wansheng Pharmaceutical Co., Ltd

7 Major Manufacturers of Repaglinide in Chinese Market, 2010-2014
7.1 Novo Nordisk A/S (Denmark)
7.2 Hanson Pharmaceutical
7.3 Tianjin Kangrui Pharmaceutical Co., Ltd
7.4 Beijing Wansheng Pharmaceutical Co., Ltd

8 Market Outlook of Repaglinide in China, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape

List of Charts

Chart Patent Registration Information of Repaglinide in China
Chart Approval Status of Repaglinide in China
Chart Sales Status of Repaglinide in China, 2010-2014
Chart Sales Value of Repaglinide in China, 2010-2014
Chart Sales Value of Repaglinide by Regions in China, 2010-2014
Chart Sales Value of Repaglinide Tablets in China, 2010-2014
Chart Sales Value of Repaglinide Capsules in China, 2010-2014
Chart Market Share of Major Manufacturers of Repaglinide for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Repaglinide Made by Novo Nordisk A/S, 2010-2014
Chart Sales Value and Market Share of Repaglinide Made by Hanson Pharmaceutical, 2010-2014
Chart Sales Value and Market Share of Repaglinide Made by Tianjin Kangrui Pharmaceutical Co., Ltd, 2010-2014
Chart Price of Repaglinide Made by Novo Nordisk A/S in Some Chinese Cities in 2014
Chart Price of Repaglinide Made by Hanson Pharmaceutical in Some Chinese Cities in 2014
Chart Price of Repaglinide Made by Tianjin Kangrui Pharmaceutical Co., Ltd in Some Chinese Cities in 2014

  • World Economic Forum Unveils Top 10 Emerging Technologies of 2016
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies of 2016. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or [...]
  • Siemens Adds To the Growth of Wind Power Generation Market
    Siemens has been presenting ground-breaking strategies and pioneering solutions for energy generation for an intelligent power supply globally. With an expansive portfolio and wide-ranging proficiency in wind power generation, Siemens is likely to aid in increasing the share of wind power in the US energy mix. With New Mexico’s vicinity to significant wind energy areas, [...]
  • Global Public Safety LTE Ecosystem Overview
    In view of its flourishing ecosystem, spectrum flexibility and performance metrics, LTE has emerged as the leading candidate for public safety mobile broadband networks. Public safety organizations and establishments have already begun planning to advance their networks to LTE-based public safety solutions. LTE provisions a varied range of services, from high bandwidth data services to [...]
  • RnR Market Research: Biochips Market Insights
    Growing R&D investment and subcontracting of pharmaceutical companies would lead to growth in biochips market in Asia along with an increase in the application of biochips products is estimated to improve opportunity for the global biochip market. Conversely, the high cost involved in manufacturing of biochips can be seen as a challenge for the same. [...]
  • Current State of Blood Banking Market, Products, Technologies and Services
    The global blood banking and blood products market is expected to reach US$41.9 billion by 2020 with USA continuing to be the largest market worldwide. Asia-Pacific follows a close second with a projected CAGR of 9.1% during this period owing to the refining healthcare infrastructure and increase in the per capita healthcare expenditure. The major [...]
  • Europe Alpha-glucosidase Inhibitors Market Report 2021
    Published: 23-Aug-2016        Price: US 4900 Onwards        Pages: 102
    This report studies sales (consumption) of Alpha-glucosidase Inhibitors in Europe market, especially in Germany, UK, France, Italy, Spain and Russia, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Sanofi - Bayer - Takeda Pharmaceuticals - Eli Lilly - Merck & Co. - Novo Nordisk - Bristol-Myers Squibb - Pfizer - AstraZeneca - GlaxoSmith......
  • Europe Antidiabetic Biguanides Market Report 2021
    Published: 23-Aug-2016        Price: US 4900 Onwards        Pages: 101
    This report studies sales (consumption) of Antidiabetic Biguanides in Europe market, especially in Germany, UK, France, Italy, Spain and Russia, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Sanofi - Takeda Pharmaceuticals - Eli Lilly - Merck & Co. - Novo Nordisk - Bristol-Myers Squibb - Pfizer - AstraZeneca - GlaxoSmithKline - Boehri......
  • Europe Antidiabetic SGLT-2 Inhibitor Market Report 2021
    Published: 23-Aug-2016        Price: US 4900 Onwards        Pages: 103
    This report studies sales (consumption) of Antidiabetic SGLT-2 Inhibitor in Europe market, especially in Germany, UK, France, Italy, Spain and Russia, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Sanofi - Johnson & Johnson - Bristol-Myers Squibb - AstraZeneca - Boehringer Ingelheim - GlaxoSmithKline - Pfizer - Takeda Pharmaceuticals - Eli L......
  • Europe Antidiabetic Sulphonylureas Market Report 2021
    Published: 23-Aug-2016        Price: US 4900 Onwards        Pages: 104
    This report studies sales (consumption) of Antidiabetic Sulphonylureas in Europe market, especially in Germany, UK, France, Italy, Spain and Russia, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Sanofi - Pfizer - Servier Laboratories - AstraZeneca - GlaxoSmithKline - Boehringer Ingelheim - Takeda Pharmaceuticals - Eli Lilly - Merck & Co.......
  • Europe Gliclazide Market Report 2021
    Published: 23-Aug-2016        Price: US 4900 Onwards        Pages: 105
    This report studies sales (consumption) of Gliclazide in Europe market, especially in Germany, UK, France, Italy, Spain and Russia, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Servier - Harbin Pharmaceutical - ... Market Segment by Regions, this report splits Europe into several key Regions, with sales (consumption), revenue, market share and growth rate of Gliclazi......
  • Europe Glipizide Market Report 2021
    Published: 23-Aug-2016        Price: US 4900 Onwards        Pages: 101
    This report studies sales (consumption) of Glipizide in Europe market, especially in Germany, UK, France, Italy, Spain and Russia, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Pfizer - TUL - Zambon - Yangtze River Pharmaceutical Group - ... Market Segment by Regions, this report splits Europe into several key Regions, with sales (consumption), revenue, ......
  • Europe Gliquidone Market Report 2021
    Published: 23-Aug-2016        Price: US 4900 Onwards        Pages: 103
    This report studies sales (consumption) of Gliquidone in Europe market, especially in Germany, UK, France, Italy, Spain and Russia, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Bayer - ... Market Segment by Regions, this report splits Europe into several key Regions, with sales (consumption), revenue, market share and growth rate of Gliquidone in these regions, from 2011 to......
  • Europe Nateglinide Market Report 2021
    Published: 23-Aug-2016        Price: US 4900 Onwards        Pages: 102
    This report studies sales (consumption) of Nateglinide in Europe market, especially in Germany, UK, France, Italy, Spain and Russia, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Novartis - Deyuan Pharm - Luoxin Pharmacy Group - ... Market Segment by Regions, this report splits Europe into several key Regions, with sales (consumption), revenue, market share and......
  • China Glimepiride Sales Market Report 2021
    Published: 22-Aug-2016        Price: US 3200 Onwards        Pages: 104
    This report studies sales (consumption) of Glimepiride in China market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Sanofi-Aventis - ... Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into - Type I - Type II - Type III Split by applications, this report focuses on sales, market share and growth rate of Glimepiride ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs